BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nam HC, Jang B, Song MJ. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma. World J Gastroenterol 2016; 22(40): 8853-8861 [PMID: 27833376 DOI: 10.3748/wjg.v22.i40.8853] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Alabraba E, Joshi H, Bird N, Griffin R, Sturgess R, Stern N, Sieberhagen C, Cross T, Camenzuli A, Davis R, Evans J, O'grady E, Palmer D, Diaz-nieto R, Fenwick S, Poston G, Malik H. Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged. European Journal of Surgical Oncology 2019;45:1660-7. [DOI: 10.1016/j.ejso.2019.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
2 Balli H, Aksungur E, Khalatai B, Aikimbaev K. Super-Selective Transarterial Chemoembolization with Doxorubicin-Loaded Drug-Eluting Beads Sized Below and Above 100 Microns in Hepatocellular Carcinoma: A Comparative Study. J Belg Soc Radiol 2019;103:47. [PMID: 31531413 DOI: 10.5334/jbsr.1841] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Albrecht KC, Aschenbach R, Diamantis I, Eckardt N, Teichgräber U. Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-µm doxorubicin-eluting microspheres. J Cancer Res Clin Oncol 2021;147:23-32. [PMID: 32880029 DOI: 10.1007/s00432-020-03370-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Aliberti C, Carandina R, Sarti D, Mulazzani L, Pizzirani E, Guadagni S, Fiorentini G. Chemoembolization Adopting Polyethylene Glycol Drug-Eluting Embolics Loaded With Doxorubicin for the Treatment of Hepatocellular Carcinoma. American Journal of Roentgenology 2017;209:430-4. [DOI: 10.2214/ajr.16.17477] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
5 Hulin A, Stocco J, Bouattour M. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. Clin Pharmacokinet 2019;58:983-1014. [PMID: 31093928 DOI: 10.1007/s40262-019-00740-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
6 Zhou GH, Han J, Sun JH, Zhang YL, Zhou TY, Nie CH, Zhu TY, Chen SQ, Wang BQ, Yu ZN, Wang HL, Chen LM, Wang WL, Zheng SS. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients. BMC Cancer 2018;18:644. [PMID: 29914435 DOI: 10.1186/s12885-018-4566-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
7 Sun J, Zhou G, Xie X, Gu W, Huang J, Zhu D, Hu W, Hou Q, Shi C, Li T, Zhang X, Ji W, Ying S, Peng Z, Zhou J, Yu Z, Ji J, Du H, Guo X, Fang J, Han J, Xu H, Sun Z, Yu W, Shao G, Wu X, Hu H, Li L, Zheng J, Luo J, Chen Y, Cao G, Hu T. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres® in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres® Transarterial Chemoembolization in Liver Cancer (CTILC) Study. Oncol Res 2020;28:75-94. [PMID: 31558180 DOI: 10.3727/096504019X15662966719585] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 Aliberti C, Carandina R, Sarti D, Pizzirani E, Ramondo G, Cillo U, Guadagni S, Fiorentini G. Transarterial chemoembolization with DC Bead LUMI™ radiopaque beads for primary liver cancer treatment: preliminary experience. Future Oncology 2017;13:2243-52. [DOI: 10.2217/fon-2017-0364] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
9 Yanagie H, Fujino T, Yanagawa M, Terao T, Imagawa T, Fujihara M, Morishita Y, Mizumachi R, Murata Y, Dewi N, Ono Y, Ikushima I, Seguchi K, Nagata M, Nonaka Y, Furuya Y, Hisa T, Nagasaki T, Arimori K, Nakashima T, Sugihara T, Kakimi K, Ono M, Nakajima J, Eriguchi M, Higashi S, Takahashi H. Tumor Growth Suppression With Novel Intra-arterial Chemotherapy Using Epirubicin-entrapped Water-in-oil-in-water Emulsion In Vivo. In Vivo 2021;35:239-48. [PMID: 33402470 DOI: 10.21873/invivo.12252] [Reference Citation Analysis]
10 Gao Y, Lyu L, Feng Y, Li F, Hu Y. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. Int J Med Sci 2021;18:3066-81. [PMID: 34400877 DOI: 10.7150/ijms.59930] [Reference Citation Analysis]
11 Li X, Li B, Ullah MW, Panday R, Cao J, Li Q, Zhang Y, Wang L, Yang G. Water-stable and finasteride-loaded polyvinyl alcohol nanofibrous particles with sustained drug release for improved prostatic artery embolization — In vitro and in vivo evaluation. Materials Science and Engineering: C 2020;115:111107. [DOI: 10.1016/j.msec.2020.111107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Hoyer M, Goli R, Barnett KK, Raabe EH, Hong K. Treatment of Hepatoblastoma With Drug-eluting Bead Transarterial Chemoembolization in a 13-Month-Old Infant: A Case Report and Review of the Literature. J Pediatr Hematol Oncol 2021;43:e123-6. [PMID: 32459718 DOI: 10.1097/MPH.0000000000001842] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Razi M, Jianping G, Xu H, Ahmed MJ. Conventional versus drug-eluting bead transarterial chemoembolization: A better option for treatment of unresectable hepatocellular carcinoma. J Interv Med 2021;4:11-4. [PMID: 34805941 DOI: 10.1016/j.jimed.2020.10.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Chen S, Ji R, Shi X, Wang Z, Zhu D. Retrospective analysis of efficacy, safety, and prognostic factors in a cohort of Chinese hepatocellular carcinoma patients treated with drug-eluting bead transarterial chemoembolization. Braz J Med Biol Res 2019;52:e8467. [PMID: 31800729 DOI: 10.1590/1414-431X20198467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Kloth C, Thaiss WM, Kärgel R, Grimmer R, Fritz J, Ioanoviciu SD, Ketelsen D, Nikolaou K, Horger M. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT. Acad Radiol 2017;24:1352-63. [PMID: 28652049 DOI: 10.1016/j.acra.2017.05.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
16 Fiorentini G, Sarti D, Carandina R, Mulazzani L, Mincarelli C, Candelari R, Argirò R, Fiorentini C, Aliberti C. A review discussing the use of polyethylene glycol microspheres in the treatment of hepatocellular carcinoma. Future Oncology 2019;15:695-703. [DOI: 10.2217/fon-2018-0425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Hu J, Albadawi H, Chong BW, Deipolyi AR, Sheth RA, Khademhosseini A, Oklu R. Advances in Biomaterials and Technologies for Vascular Embolization. Adv Mater 2019;31:e1901071. [PMID: 31168915 DOI: 10.1002/adma.201901071] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
18 Chang PY, Cheng CY, Hon JS, Kuo CD, Yen CL, Chai JW. Traditional versus Microsphere Embolization for Hepatocellular Carcinoma: An Effectiveness Evaluation Using Data Mining. Healthcare (Basel) 2021;9:929. [PMID: 34442066 DOI: 10.3390/healthcare9080929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Melchiorre F, Patella F, Pescatori L, Pesapane F, Fumarola E, Biondetti P, Brambillasca P, Monaco C, Ierardi AM, Franceschelli G, Carrafiello G. DEB-TACE: a standard review. Future Oncol. 2018;14:2969-2984. [PMID: 29987957 DOI: 10.2217/fon-2018-0136] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
20 Kong D, Jiang T, Liu J, Jiang X, Liu B, Lou C, Zhao B, Carroll SL, Feng G. Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal. Drug Deliv 2020;27:1729-40. [PMID: 33307843 DOI: 10.1080/10717544.2020.1856219] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Hatlevik Ø, Jensen M, Steinhauff D, Wei X, Huo E, Jedrzkiewicz J, Cappello J, Cheney D, Ghandehari H. Translational Development of a Silk-Elastinlike Protein Polymer Embolic for Transcatheter Arterial Embolization. Macromol Biosci 2022;:e2100401. [PMID: 34978152 DOI: 10.1002/mabi.202100401] [Reference Citation Analysis]
22 Li X, Ji X, Chen K, Yuan X, Lei Z, Ullah MW, Xiao J, Yang G. Preparation and evaluation of ion-exchange porous polyvinyl alcohol microspheres as a potential drug delivery embolization system. Mater Sci Eng C Mater Biol Appl 2021;121:111889. [PMID: 33579501 DOI: 10.1016/j.msec.2021.111889] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Vogl TJ, Gruber-Rouh T. HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer. Dig Dis Sci 2019;64:959-67. [PMID: 30835030 DOI: 10.1007/s10620-019-05542-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
24 Haubold J, Reinboldt MP, Wetter A, Li Y, Ludwig JM, Lange C, Wedemeyer H, Schotten C, Umutlu L, Theysohn J. DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies. Rofo 2020;192:862-9. [PMID: 32131109 DOI: 10.1055/a-1111-9955] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]